Previously, the selectivity of ISIRIB in targeting translational control of p-eIF2α has been studied by different reports, where it has been used in studies in mice such as treatment of neurodegeneration (Halliday et al., 2015; Wong et al., 2018), aggressive prostate cancer (Nguyen et al., 2018), in enhancing memory and memory consolidation in mice (Sidrauski et al., 2013), cognitive deficits after traumatic brain (Chou et al., 2017) and in rescuing impaired sociability and anxiety-like behavior (Kabir et al., 2017). The gene discussed is EIF2A; the disease is prostate carcinoma.